Patients with gastric cancer have a variety of immunological abnormalities. In the present study the lymphocytes and their subsets were determined in the peripheral blood of patients with gastric cancer (N = 41) both before and after surgical treatment. The percent of helper/inducer CD4 T cells (43.6 ± 8.9) was not different after tumor resection (43.6 ± 8.2). The percent of the cytotoxic CD8+ T cell population decreased significantly, whether patients were treated surgically (27.2 ± 5.8%, N = 20) or not (27.3 ± 7.3%, N = 20) compared to individuals with inflammatory disease (30.9 ± 7.5%) or to healthy individuals (33.2 ± 7.6%). The CD4/CD8 ratio consequently increased in the group of cancer patients. The peripheral blood lymphocytes of gastric cancer patients showed reduced responsiveness to mitogens. The defective blastogenic response of the lymphocytes was not associated with the production of transforming growth factor beta (TGF-ß) since the patients with cancer had reduced production of TGF-ß1 (269 ± 239 pg/ml, N = 20) in comparison to the normal individuals (884 ± 175 pg/ml, N = 20). These results indicate that the immune response of gastric cancer patients was not significantly modified by surgical treatment when evaluated four weeks after surgery and that the immunosuppression observed was not due to an increase in TGF-ß1 production by peripheral leukocytes.

Pilocarpine is a cholinergic agonist that increases salivary flow and has been used to treat xerostomia. Oral intake is the most frequent route of administration. Adverse effects are dose-dependent and include sudoresis, facial blushing and increased urinary frequency. The objective of the present study was to evaluate the effects of topical pilocarpine solutions as mouthwashes on salivary flow and their adverse effects on healthy subjects. Forty volunteers received 10 ml 0.5, 1 and 2% pilocarpine solutions or 0.9% saline in a randomized, double-blind, placebo-controlled manner. Salivation was measured before and 45, 60 and 75 min after mouth rinsing for 1 min with 10 ml of saline or pilocarpine solutions. Vital signs were measured and ocular, gastrointestinal and cardiovascular symptoms, anxiety and flushing were estimated using visual analog scales. There was a dose-dependent increase in salivation. Salivation measured after 1 and 2% pilocarpine (1.4 ± 0.36 and 2.22 ± 0.42 g, respectively) was significantly (P<0.001) higher than before (0.70 ± 0.15 and 0.64 ± 0.1 g), with a plateau between 45 and 75 min. Cardiovascular, visual, gastrointestinal and behavioral symptoms and signs were not changed by topical pilocarpine. Mouth rinsing with pilocarpine solutions at concentrations of 1 to 2% induced a significant objective and subjective dose-dependent increase in salivary flow, similar to the results reported by others studying the effect of oral 5 mg pilocarpine. The present study revealed the efficacy of pilocarpine mouthwash solutions in increasing salivary flow in healthy volunteers, with no adverse effects. Additional studies on patients with xerostomia are needed.

As estenoses benignas do esôfago (EBE) são complicações muito freqüentes, resultado de várias etiologias, a saber: refluxo gastro-esofágico, ingestão de agentes corrosivos, pós-cirurgias do esôfago, pós-radioterapia no tórax, pós-escleroterapia endoscópica de varizes do esôfago, ingestão de medicamentos, uso prolongado de cateter nasogástrico, compressão extrínseca e membranas esofágicas congênitas. As dilatações esofágicas são recomendadas no tratamento dessa complicação, empregando dilatadores de vários tipos e diâmetros, facilitando ao doente a ingestão alimentar. OBJETIVOS: Avaliação dos resultados e vantagens do tratamento conservador das EBE através de dilatações esofágicas realizadas ambulatorialmente com auxílio da endoscopia digestiva flexível. MÉTODOS: No período de 1981 a 1999 foram tratados, conservadoramente e seguidos no Gastrocentro -- UNICAMP, 500 doentes com EBE, através de um Programa de Dilatações Esofágicas instituído para cada caso. A maioria era do sexo masculino (59,2%) e a faixa etária mais acometida encontra-se entre 31 anos e 60 anos, compreendendo 52,8% dos pacientes em estudo. As estenoses mais prevalentes foram as estenoses pépticas (30,4%), cáusticas (23,6%), de anastomoses (23,2%), por megaesôfago (8,0%) e por uso prolongado de cateter nasogástrico (6,4%), perfazendo um total de 91,6% das EBE. Quanto ao número de procedimentos, 94,2% dos casos foram submetidos a no máximo 25 dilatações do esôfago. Em 95,6% deles foram utilizados dilatadores com diâmetro entre 10,5 mm e 16,0 mm. A duração do tratamento foi até 24 meses em 76,2% dos casos. Perfurações esofágicas ocorreram em seis doentes (1,2%), sem mortalidade. RESULTADOS: Foram considerados bons em 76,2%, regulares em 18,2% e maus em 5,6% dos doentes. O sucesso do tratamento variou conforme a etiologia da estenose, ocorrendo bons resultados em 81,0% das estenoses pépticas, em 66,1% das estenoses cáusticas e em 82,7% das estenoses de anastomoses. A falha do tratamento conservador ocorreu em 9,3% das estenoses cáusticas, 4,3% das estenoses de anastomose e 3,9% das estenoses pépticas. A estenose cáustica propiciou a falha maior da terapêutica conservadora em relação aos demais. CONCLUSÃO: O tratamento conservador, através de dilatações orientadas por fio-guia (Savary-Gilliard e Eder Puestow), é a primeira escolha nas EBE; é eficaz a longo prazo, com índice mínimo de complicações e o tratamento cirúrgico é apenas indicado se não for possível realizar as dilatações.

The benign esophageal stenoses (BES) are common complications owing to many etiologies: gastroesophageal reflux, ingestion of corrosive agents, esophageal surgery, radiotherapy, postendoscopic variceal sclerotherapy, drug ingestion, prolonged nasogastric intubation, extrinsic compression and esophageal webs. Esophageal dilatations are worldwide recommended to treat this complication, employing dilators of many types and diameters and facilitating the food ingestion. PURPOSE: Evaluation of the results and advantages of the conservative treatment of the BES using esophageal dilatations, in outpatient service of upper digestive endoscopy. METHODS: During the period from 1981 to 1999, 500 patients with BES were treated and followed up at the Gastrocenter -- UNICAMP, in an individually Program of Esophageal Dilatation for each case. The highest number of cases was under ages from 31 to 60 years old (52,8%), and males (59,2%). The most predominant etiologies were: peptic stenosis (30,4%), caustic ingestion (23,6%), anastomosis (23,2%), megaesophagus (8,0%) and prolonged nasogastric ingestion entubation (6,4%), totalizing 91,6% of the BES. Most of patients (94,2%) were submitted to the maximum of 25 dilations. Dilators from 10,5 to 16 mm were employed in 95,6% of the cases. The duration of the treatment was 24 months in 76,2% of the BES. Esophageal perforations occurred in 6 patients (1,2%), without mortality. RESULTS: Were considered excellent, good and bad results, respectively in 76,2%, 18,2% and 5,6% of the cases. On the other hand, excellent results were recorded in 81,0% of the peptic stenosis, 66,1% of the caustic stenosis and 82,7% of the anastomotic stenosis. The conservative treatment failed in 9,3% of the caustic stenosis, 4,3% of the anastomotic stenosis and 3,9% of the peptic stenosis. Thus, the caustic stenosis were unsuccessfull in the highest percentage of unsuccessful. CONCLUSION: The conservative treatment using guidewire dilators (Savary-Gilliard and Eder-Puestow) is the first choice in the BES, is effective for long time, with short complications and the surgical treatment is indicated only when the dilatations failed.

Fatty acids have various effects on immune and inflammatory responses, acting as intracellular and intercellular mediators. Polyunsaturated fatty acids (PUFAs) of the omega-3 family have overall suppressive effects, inhibiting lymphocyte proliferation, antibody and cytokine production, adhesion molecule expression, natural killer cell activity and triggering cell death. The omega-6 PUFAs have both inhibitory and stimulatory effects. The most studied of these is arachidonic acid that can be oxidized to eicosanoids, such as prostaglandins, leukotrienes and thromboxanes, all of which are potent mediators of inflammation. Nevertheless, it has been found that many of the effects of PUFA on immune and inflammatory responses are not dependent on eicosanoid generation. Fatty acids have also been found to modulate phagocytosis, reactive oxygen species production, cytokine production and leukocyte migration, also interfering with antigen presentation by macrophages. The importance of fatty acids in immune function has been corroborated by many clinical trials in which patients show improvement when submitted to fatty acid supplementation. Several mechanisms have been proposed to explain fatty acid modulation of immune response, such as changes in membrane fluidity and signal transduction pathways, regulation of gene transcription, protein acylation, and calcium release. In this review, evidence is presented to support the proposition that changes in cell metabolism also play an important role in the effect of fatty acids on leukocyte functioning, as fatty acids regulate glucose and glutamine metabolism and mitochondrial depolarization.